NASDAQ:PRQR ProQR Therapeutics (PRQR) News Today $1.89 +0.04 (+2.16%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.81▼$1.9250-Day Range$1.67▼$3.5952-Week Range$0.68▼$3.85Volume325,800 shsAverage Volume377,297 shsMarket Capitalization$152.74 millionP/E RatioN/ADividend YieldN/APrice Target$4.35 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Media Mentions By Week PRQR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼1.090.56▲Average Medical News Sentiment PRQR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼52▲PRQR Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAnalysts Offer Predictions for ProQR Therapeutics' FY2024 Earnings (NASDAQ:PRQR)americanbankingnews.com - May 30 at 2:00 AMProQR Therapeutics (NASDAQ:PRQR) to Post FY2024 Earnings of ($0.51) Per Share, Chardan Capital Forecastsmarketbeat.com - May 29 at 2:28 AMM28 Capital Management LP Grows Stake in ProQR Therapeutics (NASDAQ:PRQR)marketbeat.com - May 26 at 2:50 PMProQR Therapeutics (NASDAQ:PRQR) to Post FY2023 Earnings of ($0.47) Per Share, Cantor Fitzgerald Forecastsamericanbankingnews.com - May 24 at 1:38 AMChardan Capital Remains a Hold on ProQR (PRQR)markets.businessinsider.com - May 23 at 8:56 PMProQR Therapeutics (NASDAQ:PRQR) Lifted to "Hold" at StockNews.comamericanbankingnews.com - May 23 at 2:32 AMBrokers Set Expectations for ProQR Therapeutics' FY2023 Earnings (NASDAQ:PRQR)marketbeat.com - May 22 at 1:43 AMProQR Therapeutics (NASDAQ:PRQR) Price Target Cut to $4.50americanbankingnews.com - May 21 at 2:38 AMAnalysts Set Expectations for ProQR Therapeutics' Q2 2023 Earnings (NASDAQ:PRQR)americanbankingnews.com - May 21 at 1:30 AMProQR Therapeutics to Post Q4 2023 Earnings of $0.36 Per Share, HC Wainwright Forecasts (NASDAQ:PRQR)americanbankingnews.com - May 20 at 3:58 AMQ2 2023 EPS Estimates for ProQR Therapeutics Increased by Analyst (NASDAQ:PRQR)marketbeat.com - May 19 at 7:33 AMProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitabilityfinance.yahoo.com - May 18 at 9:53 AMHC Wainwright & Co. Reiterates ProQR Therapeutics N.V (PRQR) Buy Recommendationmsn.com - May 17 at 6:57 PMJMP Securities Reiterates ProQR Therapeutics N.V (PRQR) Market Outperform Recommendationmsn.com - May 17 at 6:57 PMAnalyst Ratings for ProQR Therapeuticsmsn.com - May 17 at 1:57 PMH.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)markets.businessinsider.com - May 17 at 7:39 AMRecap: ProQR Therapeutics Q1 Earningsmsn.com - May 16 at 4:39 PMProQR Announces First Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - May 16 at 9:11 AMProQR Therapeutics (NASDAQ:PRQR) Downgraded by StockNews.com to "Sell"americanbankingnews.com - May 13 at 6:40 AMProQR Therapeutics (NASDAQ:PRQR) Lowered to Sell at StockNews.commarketbeat.com - May 12 at 10:20 PMProQR Therapeutics (NASDAQ:PRQR) Short Interest Down 20.2% in Aprilmarketbeat.com - May 12 at 11:16 AMProQR Therapeutics (NASDAQ:PRQR) Receives $4.45 Average Price Target from Analystsamericanbankingnews.com - May 12 at 2:52 AMProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023finance.yahoo.com - May 9 at 12:36 PMProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Analystsmarketbeat.com - May 9 at 1:40 AMBank of Montreal Can Makes New Investment in ProQR Therapeutics (NASDAQ:PRQR)marketbeat.com - May 4 at 4:48 AMProQR Announces Upcoming Investor Conferences in April and Mayfinance.yahoo.com - April 20 at 10:33 AMProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023finance.yahoo.com - April 18 at 10:26 AMAnalysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $4.45americanbankingnews.com - April 17 at 2:48 AMProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - April 14 at 2:36 AMProQR Therapeutics (NASDAQ:PRQR) PT Lowered to $2.25 at Citigroupamericanbankingnews.com - April 10 at 2:36 AMCitigroup Cuts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.25marketbeat.com - April 7 at 3:22 PMProQR Therapeutics to Post Q1 2023 Earnings of ($0.17) Per Share, HC Wainwright Forecasts (NASDAQ:PRQR)americanbankingnews.com - April 4 at 1:18 AMProQR Therapeutics (NASDAQ:PRQR) Lifted to Hold at StockNews.comamericanbankingnews.com - April 3 at 2:00 AMBrokers Set Expectations for ProQR Therapeutics' Q1 2023 Earnings (NASDAQ:PRQR)marketbeat.com - April 3 at 1:24 AMProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to Holdmarketbeat.com - March 31 at 10:05 PMAnalysts Offer Predictions for ProQR Therapeutics' Q4 2023 Earnings (NASDAQ:PRQR)americanbankingnews.com - March 31 at 8:00 AMProQR Therapeutics (NASDAQ:PRQR) Given New $5.00 Price Target at HC Wainwrightamericanbankingnews.com - March 31 at 7:06 AMProQR Therapeutics (NASDAQ:PRQR) Price Target Increased to $5.00 by Analysts at HC Wainwrightamericanbankingnews.com - March 31 at 7:06 AMEquities Analysts Set Expectations for ProQR Therapeutics' Q4 2023 Earnings (NASDAQ:PRQR)marketbeat.com - March 31 at 6:51 AMProQR Therapeutics Stock (NASDAQ:PRQR), Earnings Estimates, EPS, and Revenuebenzinga.com - March 31 at 12:54 AMPositive Report for ProQR (PRQR) from JMP Securitiesmarkets.businessinsider.com - March 30 at 9:52 AMJMP Securities Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Outperformamericanbankingnews.com - March 30 at 7:46 AMProQR Therapeutics N.V.: ProQR Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology at R&D Eventfinanznachrichten.de - March 29 at 2:49 PMWhy Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionmsn.com - March 29 at 2:49 PMWhy Shares of ProQR Therapeutics Dropped on Wednesdayfool.com - March 29 at 12:42 PMProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Eventfinance.yahoo.com - March 29 at 9:48 AMEarnings Outlook For ProQR Therapeuticsmsn.com - March 28 at 1:09 PMProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Hold" from Brokeragesamericanbankingnews.com - March 25 at 3:50 AMProQR Therapeutics (NASDAQ:PRQR) Receives Consensus Recommendation of "Hold" from Analystsmarketbeat.com - March 20 at 2:15 AMProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.commarketbeat.com - March 15 at 1:14 AM Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: G1 Therapeutics News Today Mereo BioPharma Group News Today Greenwich LifeSciences News Today DURECT News Today ProPhase Labs News Today Esperion Therapeutics News Today Organigram News Today Alaunos Therapeutics News Today Affimed News Today Puma Biotechnology News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:PRQR) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.